Together, our findings demonstrate that activation of S6 in tumor cells is prognostic of therapeutic response in diverse models of breast cancer and represents a potential biomarker to distinguish for which tumors combination of PI3K/Akt/mTOR inhibitors with anti-endocrine therapies would be beneficial, and for which they could have the potential to be detrimental. This evidence concerns the gene AKT1 and breast carcinoma.